company background image
ILU

Illumina XTRA:ILU Stock Report

Last Price

€195.08

Market Cap

€30.4b

7D

-1.1%

1Y

-38.8%

Updated

31 Jan, 2023

Data

Company Financials +

ILU Stock Overview

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.

ILU fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 15.2% below our estimate of its fair value

Earnings are forecast to grow 62.83% per year

Risk Analysis

No risks detected for ILU from our risk checks.

My Notes

New

Notes are coming soon

Illumina, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Illumina
Historical stock prices
Current Share PriceUS$195.08
52 Week HighUS$337.50
52 Week LowUS$165.40
Beta1.13
1 Month Change4.31%
3 Month Change-11.00%
1 Year Change-38.77%
3 Year Change-27.86%
5 Year Change7.23%
Change since IPO1,146.92%

Recent News & Updates

Recent updates

Shareholder Returns

ILUDE Life SciencesDE Market
7D-1.1%2.6%0.3%
1Y-38.8%-19.9%-11.1%

Return vs Industry: ILU underperformed the German Life Sciences industry which returned -19.9% over the past year.

Return vs Market: ILU underperformed the German Market which returned -11.1% over the past year.

Price Volatility

Is ILU's price volatile compared to industry and market?
ILU volatility
ILU Average Weekly Movement6.1%
Life Sciences Industry Average Movement6.0%
Market Average Movement5.2%
10% most volatile stocks in DE Market10.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ILU is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ILU's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19989,825Francis deSouzahttps://www.illumina.com

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services.

Illumina, Inc. Fundamentals Summary

How do Illumina's earnings and revenue compare to its market cap?
ILU fundamental statistics
Market Cap€30.43b
Earnings (TTM)-€3.82b
Revenue (TTM)€4.33b

7.0x

P/S Ratio

-8.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ILU income statement (TTM)
RevenueUS$4.70b
Cost of RevenueUS$1.42b
Gross ProfitUS$3.28b
Other ExpensesUS$7.44b
Earnings-US$4.15b

Last Reported Earnings

Oct 02, 2022

Next Earnings Date

Feb 07, 2023

Earnings per share (EPS)-26.40
Gross Margin69.83%
Net Profit Margin-88.36%
Debt/Equity Ratio25.9%

How did ILU perform over the long term?

See historical performance and comparison